Shots: The approval is based on P-III THALES study involves assessing Brilinta (180mg as a loading dose followed by 90mg, bid) + aspirin vs aspirin as monothx. in 11,000 patients […]readmore
Tags : Brilinta
Shots: The P-III THALES study involves assessing of Brilinta (180mg as a loading dose followed by 90mg, bid) + aspirin vs aspirin as monothx. in 11,000 patients with non-cardioembolic acute […]readmore
Shots: The US FDA has accepted sNDA and granted PR for Brilinta to reduce subsequent stroke in patients experiencing an acute ischemic stroke or TIA. The sNDA is based on […]readmore
Shots: The P-III THALES study involves assessing of Brilinta (90mg, bid) + aspirin vs aspirin as monothx. in 11,000+ patients with minor acute ischemic stroke or high-risk TIA in the […]readmore
Shots: The P-III THEMIS study involves assessing of Brilinta + Aspirin vs Aspirin as monothx. in 19,000+ patients with CAD and T2D with no prior myocardial infarction or stroke across […]readmore
Shots: The P-III THEMIS study involves assessing of Brilinta (ticagrelor) + aspirin vs aspirin monothx in patients with coronary artery disease (CAD) and type-2 diabetes (T2D) with no prior myocardial […]readmore